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Introduction
Myocardial injury triggers a complex series of  inflammatory responses that result in the recruitment 
and activation of  cells of  the innate and adaptive immune systems. This brisk inflammatory response 
upregulates a suite of  cytoprotective and/or reparative responses that provide the heart with short-term 
adaptations to environmental stress (reviewed in ref. 1). However, this same inflammatory response 
often results in unintended collateral myocardial damage that can lead to adverse left ventricular (LV) 
remodeling and progressive dysfunction. Although there have been a number of  clinical attempts to 
target inflammation following cardiac injury (reviewed in ref. 2), there are currently no FDA-approved 
immunomodulatory therapies for the treatment of  acute myocardial injury.
Pirfenidone is an orally active pyridinone derivative whose mechanism of  action is not fully under-
stood. Pirfenidone has been shown to have antifibrotic, antiinflammatory, and antioxidant properties 
(3), and is currently FDA approved for the treatment of  idiopathic pulmonary fibrosis. Pirfenidone has 
also been shown to be protective in the heart in a number of  different experimental models of  cardiac 
injury including transverse aortic constriction (4, 5), angiotensin II–induced cardiac hypertrophy (6), 
DOCA salt hypertensive cardiomyopathy (7), Duchenne muscular dystrophy–associated cardiomyop-
athy (8), diabetes-associated cardiomyopathy (9), tachycardia-induced cardiomyopathy (10), and myo-
cardial infarction (11, 12). While the majority of  the cardioprotective effects of  pirfenidone have been 
attributed to a reduction in cardiac fibrosis, the precise cellular target and mechanism of  action for 
the cardioprotective effects of  pirfenidone in vivo remain unknown. Noting that pirfenidone has been 
shown to have a number of  different immunomodulatory properties that are relevant to immune-me-
diated collateral damage, we sought to determine whether pirfenidone would favorably modulate the 
Despite the long-standing recognition that the immune response to acute myocardial injury 
contributes to adverse left ventricular (LV) remodeling, it has not been possible to effectively 
target this clinically. Using 2 different in vivo models of acute myocardial injury, we show that 
pirfenidone confers beneficial effects in the murine heart through an unexpected mechanism 
that depends on cardiac B lymphocytes. Naive hearts contained a large population of 
CD19+CD11b–CD23–CD21–IgD+IgMlo lymphocytes, and 2 smaller populations of CD19+CD11b+ B1a 
and B1b cells. In response to tissue injury, there was an increase in neutrophils, monocytes, 
macrophages, as well as an increase in CD19+ CD11b– B lymphocytes. Treatment with pirfenidone 
had no effect on the number of neutrophils, monocytes, or macrophages, but decreased 
CD19+CD11b– lymphocytes. B cell depletion abrogated the beneficial effects of pirfenidone. 
In vitro studies demonstrated that stimulation with lipopolysaccharide and extracts from 
necrotic cells activated CD19+ lymphocytes through a TIRAP-dependent pathway. Treatment 
with pirfenidone attenuated this activation of B cells. These findings reveal a previously 
unappreciated complexity of myocardial B lymphocytes within the inflammatory infiltrate 
triggered by cardiac injury and suggest that pirfenidone exerts beneficial effects in the heart 
through a unique mechanism that involves modulation of cardiac B lymphocytes.
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inflammatory response following acute cardiac injury. Here we show in 2 different models of  cardiac 
injury that unexpectedly pirfenidone exerts salutary effects through a potentially novel mechanism 
that involves the modulation of  distinct B lymphocyte populations in the heart.
Results
Pirfenidone improves survival after diphtheria toxin–mediated acute myocardial injury. To determine the effects of pir-
fenidone on acute myocardial injury we employed the diphtheria toxin (DT) cardiac myocyte cell ablation mod-
el, as previously described (13). Adult Rosa26-DTMlc2v-Cre mice injected with DT develop LV dysfunction and 
remodeling, and associated increased mortality within 2 weeks (13). As shown in Figure 1A, the survival of pir-
fenidone-treated mice was significantly improved when compared with untreated, DT-treated littermate controls 
(P = 0.03). The protective effect of pirfenidone was not secondary to a significant attenuation in DT-induced 
cardiac myocyte cell death, insofar as there were no significant differences in serum troponin levels (P = 0.34, 
Figure 1B), the prevalence of cardiac myocyte apoptosis (P = 0.39, Figure 1C), and extent of Evans blue dye 
uptake (P = 0.26, Figure 1D) between the mice fed normal chow and mice fed chow with pirfenidone.
Pirfenidone reduces cardiac CD19+ B lymphocytes following DT-mediated acute myocardial injury. Given that 
treatment with pirfenidone did not reduce cardiac myocyte necrosis or apoptosis, we asked whether pir-
fenidone improved survival by modulating the innate immune response to acute cardiac injury. Accord-
ingly, we performed FACS analysis 4 days after DT injection. The gating strategy for this FACS analysis 
is shown in Supplemental Figure 1A (supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.120137DS1). In preliminary control studies, we determined that treatment with 
pirfenidone for 1 week in naive WT hearts had no significant effect on the number of  CD45+ cells/mg 
tissue (P = 0.53), Ly6G+ neutrophils (P = 0.82), Ly6C+CD64lo/– monocytes (P = 0.81), CD64+Ly6Clo/– mac-
rophages (P = 0.82), or CD19+ B lymphocytes (P = 0.94; Supplemental Figure 1, B and C).
As shown in Figure 2, there were no significant differences in the DT-injured hearts from mice treated 
with pirfenidone chow or normal chow with respect to the number of  myocardial CD45+ cells (P = 0.8, 
Figure 2A), Ly6G+ neutrophils (P = 0.27, Figure 2B), Ly6C+CD64lo/– monocytes (P = 0.15, Figure 2B), and 
Ly6Clo/–CD64+ macrophages (P = 0.9, Figure 2B). The adult heart macrophage pool consists of  resident 
and recruited cells, the latter of  which have been associated with adverse LV remodeling following injury. 
These subpopulations are largely divided by the expression of  CCR2 and MHC-II (13, 14). Therefore, we 
further characterized the macrophage populations in control and pirfenidone-treated animals. As shown 
in Figure 2, C and D there was no significant difference in the percentage of  MHC-IIhiCCR2lo (P = 0.43), 
MHC-IIhiCCR2hi (P = 0.36), MHC-IIloCCR2hi (P = 0.21), or MHC-IIloCCR2lo (P = 0.11) macrophage sub-
sets in the presence and absence of  treatment with pirfenidone. Despite the lack of  differences in cardiac 
myeloid populations after damage, we did observe that treatment with pirfenidone resulted in a greater than 
3-fold reduction in the percentage of  CD19+ myocardial B lymphocytes following DT-induced injury (P = 
0.02, Figure 2B) when compared with mice that were fed normal chow.
Pirfenidone reduces adverse LV remodeling and cardiac CD19+ B lymphocytes after closed-chest ischemia-reperfusion 
injury. To determine the effects of pirfenidone in a more pathophysiologically relevant model of cardiac inju-
ry, we subjected control mice and pirfenidone-treated mice to closed-chest ischemia-reperfusion (I/R) injury 
(90 minutes of ischemia), as previously described (15). As shown in Figure 3A, there was no difference (P = 
0.68) in the area at risk in control and pirfenidone-treated animals, as determined by the segmental wall motion 
score index (SWMSI). Treatment with pirfenidone resulted in a significant decrease in the heart weight–to–tibia 
length ratio (Figure 3, B and C) and LV mass measured by 2-D echocardiography (P = 0.03, Figure 3D) when 
compared with control mice. Consistent with these findings, we observed a significant (P = 0.02) decrease in LV 
end-diastolic volumes (Figure 3E) in pirfenidone-treated animals when compared with control animals, whereas 
there was a trend (P = 0.08) towards improvement in LV ejection fraction (LVEF) in the treatment group (Figure 
3F). Figure 3G shows representative Masson’s trichrome staining in control and pirfenidone-treated animals, 
whereas Figure 3H summarizes the results of the group data. As shown in Figure 3H, there was no significant 
difference (P = 0.4) in the percentage of myocardium exhibiting collagen staining with Masson’s at 2 weeks, 
when the pirfenidone chow mice were compared to the mice fed normal chow.
As the preceding experiments examined the effect of  pretreatment with pirfenidone prior to I/R injury, 
we sought to determine whether the acute administration of  pirfenidone was sufficient to influence LV 
remodeling after I/R injury. We therefore treated mice with intravenous pirfenidone or diluent soon after 
reperfusion injury, followed by i.p. injections for 1 day and oral pirfenidone in the chow for 14 days. Supple-
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mental Figure 2 shows that the area at risk was not different (P = 0.47) in the control and pirfenidone-treat-
ed animals. However, the salient finding shown by Supplemental Figure 2 is that acute administration of  
pirfenidone significantly (P = 0.015) reduced the heart weight/tibia length ratio (P = 0.015, Supplemental 
Figure 2B), LV mass by 2-D echocardiography (P = 0.029, Supplemental Figure 2D), and LV end-diastolic 
volume (P = 0.037, Supplemental Figure 2E), when compared with diluent-treated control mice.
To determine whether the mechanism(s) for the beneficial effects of  pirfenidone in the closed-chest 
I/R injury model was dependent on modulation of  the innate immune response to acute cardiac injury, we 
harvested hearts on day 4 after I/R injury, and analyzed the inflammatory infiltrate via FACS. Consistent 
with the results observed with the DT-induced injury model, treatment with pirfenidone did not signifi-
cantly (P = 0.98, Figure 4A) alter the total number of  CD45+ cells per mg heart, Ly6G+ neutrophils (P = 
0.44, Figure 4B), Ly6C+CD64lo/– monocytes (P = 0.74, Figure 4B), or CD64+Ly6Clo/– macrophages (P = 
0.91, Figure 4B). Moreover, treatment with pirfenidone did not alter the relative prevalence of  macrophage 
Figure 1. Effect of pirfenidone on mortality and cardiac myocyte cell death after DT treatment. Mice expressing the 
diphtheria toxin receptor (DTR) in the myocardium were exposed to diphtheria toxin (DT) and fed either chow enriched 
with pirfenidone (DTR-PFD) or regular chow (DTR-control). (A) Kaplan-Meier survival curves of DTR control and DTR-
PFD mice (n = 20 per group). (B) Serum troponin levels measured at day 4 after DT treatment in DTR-PFD and DTR-con-
trol animals (n = 23/group). (C) Cardiac myocyte apoptosis measured at day 4 after treatment with DT. Upper panels are 
representative histological sections of myocardium from DTR-control and DTR-PFD mice at ×40 magnification. Lower 
panel summarizes the group data (n = 6 mice/group, 4 sections per animal analyzed). (D) Evans blue (EB) dye uptake at 
day 4 after DT treatment in DTR-control and DTR-PFD animals; upper panels are representative fluorescence micros-
copy images at ×10 magnification; lower panel summarizes the group data (n = 5 control; n = 6 mice with pirfenidone; 
4 sections per animal analyzed). Bars represent the mean, and error bars represent standard deviation. P values were 
calculated with the Gehan-Breslow-Wilcoxon method for panel A and with Student’s t test for panels B–D.
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subpopulations as defined by levels of  expression of  CCR2 and MHC-II (Figure 4, C and D). However, we 
again noticed that treatment with pirfenidone significantly (P = 0.004) reduced the percentage of  CD19+ B 
lymphocytes (Figure 4B) in the heart following injury.
Pirfenidone modulates subsets of  cardiac B lymphocytes following cardiac injury. To further interrogate the effects 
of  pirfenidone on cardiac B lymphocytes, we first analyzed the surface antigens of  cardiac B cells using known 
markers of  B lymphocytic subtypes. The gating strategy that was used is illustrated in Supplemental Figure 3 
and staining of  splenic B lymphocytes is provided for reference in Supplemental Figure 4. As shown in Figure 
5, the majority of  CD19+ cardiac B cells in the uninjured adult heart were CD19+CD11b–. Further characteri-
zation of  this population revealed that they were IgD+ and IgMlo/–CD21–CD23–CD11c– (Supplemental Figure 
3). Approximately 10% of the resident cardiac B cells in uninjured hearts were CD19+CD11b+. This popu-
lation of  cells was predominately CD5–IgM+, which is characteristic of  B1b lymphocytes, whereas a smaller 
percentage was CD5+IgM+, which is characteristic of  B1a lymphocytes (16) (Figure 5A).
We next analyzed B cell profiles in the presence or absence of  pirfenidone in the DT-induced injury 
model and the closed-chest I/R injury model. As shown in Figure 5, in both models of  cardiac injury, the 
relative ratio of  CD19+CD11b– cells to B1 cells on day 4 after cardiac injury remained unchanged relative 
to naive hearts. In the DT-injured hearts (day 4) there was a small but nonsignificant (Figure 5B) increase 
Figure 2. Effect of pirfenidone on myocardial inflammation (day 4) after DT treatment. Mice expressing the diphtheria toxin 
receptor (DTR) in the myocardium were exposed to diphtheria toxin (DT) and fed either chow enriched with pirfenidone (DTR-
PFD) or regular chow (DTR-control). Mice were sacrificed at day 4 after DT injection and the heart was collected for analysis via 
flow cytometry. (A) Total number of CD45+ cells/mg heart tissue (n = 17 control, n = 19 pirfenidone). (B) Leukocyte subsets in 
the myocardium (percentage of total: CD19+, n = 14 control, n = 16 pirfenidone; Ly6g+, n = 6/group, Ly6C+CD64lo/–, n = 10 control, n 
= 12 pirfenidone; CD64+Ly6Clo/–, n = 10 control, n = 12 pirfenidone). (C) Representative FACS analysis of MHC-II and CCR-2 macro-
phages and monocytes. (D) Macrophage/monocyte subsets in the myocardium as defined by expression of CCR2, low (l) or high 
(h) and MHC-II expression, low (l) or high (h). Percentage of total, n = 10 control, n = 12 pirfenidone.*P < 0.05. Bars represent the 
mean, and error bars represent standard deviation. P values were calculated with Student’s t test.
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Figure 3. Effect of pirfenidone 
on LV structure and function 
after closed-chest I/R injury. 
Wild-type mice were subjected 
to 90 minutes of closed-chest 
ischemia followed by 2 weeks 
of reperfusion (I/R injury). 
Mice were fed either chow 
enriched with pirfenidone or 
regular chow. (A) Area at risk 
during closed-chest ischemia 
as determined by the simpli-
fied segmental wall motion 
score index (SWMSI) at time of 
ischemia. (B) Representative 
pictures of hearts harvested 
from control mice (left) and 
pirfenidone-treated animals 
(right) 2 weeks after I/R injury. 
Scale bar: 1 mm. (C) Gravimet-
ric analysis of hearts harvested 
from control mice (I/R-control) 
and pirfenidone-treated ani-
mals (I/R-PFD). n = 8 control, 
n = 7 pirfenidone. (D–F) 
Echocardiographic assessment 
of myocardial function at the 
time of ischemia and 2 weeks 
after I/R injury. n = 8 I/R-con-
trol, n = 7 I/R-PFD. (D) Left 
ventricular (LV) mass (LVM) by 
2-D echocardiography. (E) LV 
end-diastolic volume (LVEDV). 
(F) LV ejection fraction (LVEF). 
(G) Representative trichrome 
staining of histological sec-
tions of hearts from control 
animals (left panel) and 
pirfenidone-treated animals 
(right panel). Original magnifi-
cation, ×1.25. (H) Quantitative 
assessment of the percentage 
trichrome-positive staining, 2 
sections analyzed per heart. n 
= 16 sections I/R-control, n = 
14 sections I/R-PFD. *P < 0.05. 
Bars represent the mean, and 
error bars represent standard 
deviation. P values were calcu-
lated with Student’s t test.
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in the number of  CD19+ cells/mg of  cardiac tissue (P = 0.09) and CD19+CD11b+ cells/mg of  cardiac tis-
sue (P = 0.14), but no change in the number of  CD19+CD11b– cells/mg of  cardiac tissue (P = 0.96) when 
compared with naive hearts. In contrast, there was a significant 2-fold increase in CD19+ (P < 0.001) and 
CD19+CD11b– (P < 0.001) cells at the same time point following I/R injury (Figure 5C). In the DT-in-
duced injury cardiac myocyte ablation model, the pirfenidone-treated animals had significantly fewer (P < 
0.01) CD19+ cells/mg of  tissue, with a significant (P = 0.04) reduction in the subset of  CD19+CD11b– cells 
(Figure 5B). We observed very similar changes in the closed-chest I/R injury model, in which pirfenidone 
treatment resulted in a significant (P < 0.001) reduction in CD19+ lymphocytes on day 4 after I/R, as well 
as a significant (P < 0.001) reduction in the subset of  CD19+CD11b– B lymphocytes (Figure 5C).
The cardioprotective effect of  pirfenidone is mediated by B lymphocytes. Viewed together, the above results 
suggest that the cardioprotective effects of  pirfenidone may be mediated, at least in part, by cardiac B lym-
phocytes. To test this hypothesis, we depleted native B cells using a commercially available anti-CD20 anti-
body, and then repeated the closed-chest I/R studies in the presence and absence of  pirfenidone. Given that 
the mice were instrumented 7 days prior to I/R injury in the closed-chest model, we injected the mice with 
anti-CD20 antibody at the time of  instrumentation. The efficiency of  anti-CD20 antibody B cell depletion 
was assessed 8 days after anti-CD20 injection (i.e., at the time that I/R injury is performed) and on day 
12 after injection (i.e., day 4 after I/R). As shown in Supplemental Figure 5, A and B, a single injection 
of  anti-CD20 antibody ablated over 99% of  splenic B cells and cardiac B cells by day 8. We noticed that 
Figure 4. Effect of pirfenidone on myocardial inflammation (day 4) after I/R injury. Wild-type mice were subjected to 90 min-
utes closed-chest ischemia followed by reperfusion (I/R injury). Mice were fed either chow enriched with pirfenidone (PFD) or regu-
lar chow. Mice were sacrificed at day 4 after I/R injury and the heart was collected for analysis via flow cytometry. n = 8 I/R-control, 
n = 4 I/R-PFD. (A) Total number of CD45+ cells/mg heart tissue. (B) Leukocyte subsets in the myocardium (percentage of total: 
CD19+, Ly6g+, Ly6C+CD64lo/–, CD64+Ly6Clo; n = 4/group). (C) Representative FACS analysis of MHC-II and CCR-2 macrophages and 
monocytes. (D) Macrophage/monocyte subsets in the myocardium as defined by expression of CCR 2, low (l) or high (h) and MHC-II 
expression, low (l) or high (h). Percentage of total, n = 4/group.***P < 0.001. Bars represent the mean, and error bars represent 
standard deviation. P values were calculated with Student’s t test.
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the number of  cardiac B cells began to 
recover on day 4 after I/R injury (i.e., 
day 12 after injection). However, the 
total number of  B cells remained less 
than 10% that of  untreated controls 
(Supplemental Figure 5C). Notably, 
while B cell depletion after I/R inju-
ry significantly reduced (P < 0.01) the 
number of  CD19+CD11b– cells, it did 
not significantly (P = 0.2) reduce the 
total number of  CD19+CD11b+ cells 
(Supplemental Figure 5C). However, 
when we examined CD19+CD11b+ 
subsets, treatment with the anti-CD20 
antibody did significantly (P = 0.05) 
reduce the number of  B1b lympho-
cytes, whereas it had no effect on the number of  cardiac B1a lymphocytes (P = 0.58, Supplemental Figure 
5C). There was no significant difference in the heart weight–to–tibia length ratio (P = 0.75, Figure 6, B 
and C), LV mass (P = 0.21, Figure 6D), LV end-diastolic volume (P = 0.40, Figure 6E), LVEF (P = 0.15, 
Figure 6F), or percentage of  trichrome-positive myocardium (P = 0.43, Figure 6, G and H) between the 
B cell–depleted mice and B cell–depleted + pirfenidone-treated mice 2 weeks after I/R injury. Thus, the 
cardioprotective effects of  pirfenidone following I/R injury were B cell dependent.
Pirfenidone modulates B cell activation through a TIRAP-dependent signaling pathway. The observation that 
B cell depletion abrogated the salutary effects of  pirfenidone suggested that the beneficial effects of  pir-
fenidone were not necessarily mediated by decreasing the number of  B cells following tissue injury, and 
raised the intriguing possibility that pirfenidone might be modulating the response of  B cells to tissue 
injury. To gain insight into the mechanism(s) responsible for the immunomodulatory effects of  pirfeni-
Figure 5. Characterization of subsets of 
myocardial B lymphocytes at baseline 
and after DT-induced injury and I/R inju-
ry. (A) Analysis of subsets of myocardial 
CD19+ B lymphocytes in naive hearts (n 
= 4). (B) Mice expressing the diphtheria 
toxin receptor (DTR) in the myocardium 
were exposed to diphtheria toxin (DT) 
and fed either regular chow (control, gray 
bars) or chow enriched with pirfenidone 
(PFD, white bars). Mice were sacrificed at 
day 4 after DT injection and the heart was 
collected for analysis of myocardial CD19+ 
B lymphocytes via flow cytometry (n = 4 
control, n = 3 pirfenidone). (C) Wild-type 
mice were subjected to 90 minutes closed-
chest ischemia followed by reperfusion 
(I/R injury). Mice were fed either regular 
chow (control, gray bars) or chow enriched 
with pirfenidone (PFD, white bars). Mice 
were sacrificed at day 4 after I/R injury 
and the heart was collected for analysis 
of myocardial CD19+ B lymphocytes via 
flow cytometry (n = 8 controls, n = 5 
pirfenidone). *P < 0.05, **P < 0.01, ***P 
< 0.001 versus control; †P < 0.001 versus 
naive hearts. Bars represent the mean, and 
error bars represent standard deviation. P 
values were calculated with 2-way ANOVA 
followed by Tukey’s test for multiple 
comparisons.
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done, we performed transcriptional profiling on CD19+CD11b+ and CD19+CD11b– cardiac lymphocytes 
that were FACS isolated from naive, DT-injured mice fed normal chow, and DT-injured mice treated with 
pirfenidone chow. As shown in Supplemental Figure 6, principal component analysis of  the transcrip-
tome of  cardiac B cells suggested that the mRNAs of  the CD19+CD11b+ (Supplemental Figure 6A) and 
CD19+CD11b– (Supplemental Figure 6B) cells from DT-injured hearts had a profile that was distinct from 
cells from naive hearts. Importantly, the transcriptional profile of  the pirfenidone-treated DT-injured mice 
clustered between the profile of  the naive and the untreated hearts, suggesting that pirfenidone modulated 
the changes in B lymphocyte gene expression that were provoked by cardiac injury. KEGG pathway anal-
ysis of  mRNAs differentially expressed greater than 2-fold (FDR < 0.05) between DT-injured and naive 
hearts identified 6 pathways that were enriched in the CD19+CD11b+ lymphocytes from the DT-injured 
hearts (Supplemental Figure 6C): hematopoietic cell lineage (P = 1 × 10–5), cytokine-cytokine receptor 
interaction (P = 3 × 10–3), B cell receptor signaling pathway (P = 1 × 10–3), cell adhesion molecules (P = 
0.04), antigen processing and presentation (P = 0.04), and MAPK signaling (P = 0.05). These pathways 
were not activated in the CD19+CD11b+ lymphocytes isolated from the DT receptor (DTR) + pirfenidone 
hearts (Supplemental Figure 6C), demonstrating that pirfenidone alters the gene expression changes in B 
cells that are driven by cardiac injury. As shown in Supplemental Figure 6D, the KEGG pathway analysis 
identified 5 pathways in CD19+CD11b– cells: 2 pathways that were also activated in the CD19+CD11b+, 
specifically hematopoietic cell lineage (P = 2 × 10–3) and cytokine-cytokine receptor interaction (P = 1 × 
10–3); as well as 3 unique pathways, specifically Toll-like receptor (TLR) signaling (P = 1 × 10–3), TNF 
signaling pathway (P = 7 × 10–3), and chemokine receptor signaling pathway (P = 0.02). With the excep-
tion of  the hematopoietic cell lineage pathway, none of  these pathways was significantly enriched in the 
CD19+CD11b– lymphocytes isolated from the DTR + pirfenidone hearts (Supplemental Figure 6D). The 
gene lists for each of  these KEGG pathways are provided in Supplemental Tables 1 and 2. Viewed together, 
these studies suggest that myocardial CD19+CD11b+ and CD19+CD11b– lymphocytes share common bio-
logical responses, but also have unique biological responses to tissue injury, and that both of  these common 
and unique responses to cardiac injury are modulated by pirfenidone.
Noting that prior studies have shown that B cells are activated by engagement of  TLR by damage-asso-
ciated molecular patterns (DAMPs) released by necrotic cells (17), and noting that TLR signaling was pres-
ent in CD19+CD11b– lymphocytes sorted from DT-injured animals but absent in the same cells sorted from 
DT-injured animals treated with pirfenidone, we focused our in vitro studies on CD19+ cells using LPS (a 
classic TLR4 agonist and a T-independent antigen), as well as necrotic cardiac cell extracts, which we and 
others have shown signal through TLR4 (18). Based on a prior study which showed that activation of  TLR 
signaling was a strong inducer of  the costimulatory molecule CD86 in cultured B cells (19), we used upreg-
ulation of  CD86 as a marker of  B cell activation. As shown in Figure 7A, stimulation of  peritoneum-de-
rived inflammatory cells (PDICs) with LPS or cytosolic extracts from necrotic cells provoked a robust (P < 
0.001 for both) increase in the CD19+CD86hi lymphocytes. Importantly, the number of  CD19+CD86hi was 
significantly attenuated (P < 0.001 for both) by pirfenidone. To further explore the role of  TLR-mediated 
signaling, we repeated these experiments in PDICs obtained from thioglycolate-stimulated TIRAP–/– mice. 
As shown in Figure 7B, necrotic cytosolic extracts did not provoke a significant increase in the percentage 
of  CD19+CD86hi lymphocytes, whereas LPS stimulation resulted in a significant increase in the percent-
age of  CD19+CD86hi lymphocytes (P < 0.001), albeit to a lesser extent than was observed in PDICs from 
TIRAP+/+ mice. Notably, treatment with pirfenidone resulted in a small but significant (P < 0.001) decrease 
in CD19+CD86hi lymphocytes in LPS-simulated cultures. These findings suggest that, in the context of  a 
mixed population of  inflammatory cells, necrotic cytosolic extracts modulate expression of  costimulato-
ry molecules on B cells through a TIRAP-dependent mechanism, whereas LPS modulates expression of  
costimulatory molecules on B cells through a mechanism that is TIRAP independent. Importantly, both 
mechanisms were sensitive to treatment with pirfenidone (Figure 7, A and B).
We next sought to determine whether the response of  B cells to necrotic cytosolic extracts and LPS 
were cell autonomous, by repeating the above in vitro experiments in purified B lymphocytes harvested 
from the spleen. Interestingly, while the effect of  LPS on purified B cells was very similar to that observed 
on PDICs, the effect of  necrotic cytosolic extracts was greatly attenuated. As shown in Figure 7C, LPS 
provoked a significant (P < 0.001) increase in CD19+CD86hi cells that was partially sensitive to inhibition 
with pirfenidone. In contrast, necrotic cytosolic extracts induced a small, non–statistically significant (P = 
0.62) upregulation of  CD19+CD86hi B cells when compared with diluent-treated cells (Figure 7C). Similar 
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Figure 6. Effect of B cell 
depletion on pirfenidone 
cardioprotective effect after 
I/R injury. Wild-type mice 
were B cell depleted via injec-
tion of anti-CD20 antibody. 
Seven days after injection of 
anti-CD20 antibody, B cell–
depleted mice were subjected 
to 90 minutes of closed-chest 
ischemia followed by reper-
fusion (I/R injury). Mice were 
fed either chow enriched with 
pirfenidone (anti-CD20 PFD) 
or regular chow (anti-CD20 
control). (A) Area at risk during 
closed chest-ischemia as 
determined by the simplified 
segmental wall motion score 
index (SWMSI) at time of 
ischemia. (B) Representative 
pictures of hearts harvested 
from anti-CD20–treated mice 
(left) and anti-CD20 + pirfeni-
done–treated animals (right). 
Scale bar: 1 mm. (C) Gravimet-
ric analysis of hearts harvested 
from pirfenidone-treated 
animals (anti-CD20 PFD) and 
untreated controls (anti-CD20 
control), n = 7/group. (D–F) 
Echocardiographic assess-
ment of myocardial function 
at the time of ischemia and 2 
weeks after I/R injury, n = 7/
group. Data from non–anti-
CD20–treated animals already 
reported in Figure 3, D–F are 
shown again for compari-
son only (control). (D) Left 
ventricular (LV) mass (LVM) by 
2-D echocardiography. (E) LV 
end-diastolic volume (LVEDV). 
(F) LV ejection fraction (LVEF). 
(G) Representative trichrome 
staining of histological sec-
tions of hearts from control 
animals (left panel) and 
pirfenidone-treated animals 
(right panel). Original magnifi-
cation, ×1.25. (H) Quantitative 
assessment of the percentage 
of trichrome-positive staining, 
2 sections analyzed per heart, 
n = 10 sections/group. Bars 
represent the mean, and error 
bars represent standard devia-
tion. P values were calculated 
with Student’s t test.
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results were obtained in splenic B lymphocytes from TIRAP–/– animals (Figure 7D). Viewed together, these 
findings suggest that the B cell response to LPS and its modulation by pirfenidone are cell autonomous, and 
are mediated, at least in part, through TIRAP-dependent signaling. In contrast, the response of  B cells to 
necrotic cell extracts (NCEs) and the immunomodulatory effects of  pirfenidone are non–cell autonomous, 
which suggest that they are likely to be context and tissue dependent.
To determine whether our findings with respect to activation of  CD19+ B cells in vitro were relevant in 
vivo, we measured the number of  myocardial CD19+CD86hi B cells isolated from the hearts of  mice from 
the DT-induced injury model and the closed-chest I/R model in the presence and absence of  pirfenidone. 
As shown in Figure 7E, treatment with pirfenidone was associated with a significant (P < 0.04) decrease 
in the number of  myocardial CD19+CD86hi B lymphocytes in the DT-induced injury model and Figure 7F 
shows that treatment with pirfenidone was associated with a significant (P < 0.03) decrease in the number 
of  myocardial CD19+CD86hi B cells following I/R injury.
Discussion
In this study, we investigated the cardioprotective effects of  pirfenidone, a small molecule that is FDA 
approved for the treatment of  idiopathic pulmonary fibrosis, and provide evidence that pirfenidone exerts 
beneficial effects in the heart through a potentially unique mechanism that involves immune modulation of  
the cardiac B lymphocyte response to tissue injury. The following lines of  evidence support this statement. 
First, treatment with pirfenidone resulted in improved survival in a genetic model of  cardiac myocyte inju-
ry. Notably, the improved survival was not secondary to a decrease in apoptotic or necrotic cardiac myocyte 
cell death (Figure 1). Moreover, the improved survival was not secondary to decreased influx of  Ly6G+ 
neutrophils, Ly6C+CD64lo/– monocytes, or CD64+Ly6Clo/– macrophages. Rather, we observed a significant 
decrease in the number of  CD19+ lymphocytes in the heart following pirfenidone treatment (Figure 2). Sec-
ond, treatment with pirfenidone significantly reduced cardiac remodeling after closed-chest I/R injury, as 
demonstrated by a decrease in the heart weight–to–tibia length ratio, LV mass, and LV end diastolic volume 
(Figure 3). Importantly, the salutary effects of  pirfenidone were present whether animals were pretreated 
with the drug or it was administered after I/R injury (Supplemental Figure 2). The attenuation in LV 
remodeling was not secondary to decreased influx of  Ly6G+ neutrophils, Ly6C+CD64lo/–, monocytes, or 
CD64+Ly6Clo/– macrophages (Figure 4). Similar to the observations made in the DT-induced injury model, 
we observed a significant decrease in CD19+ lymphocytes in the heart following pirfenidone treatment 
(Figure 4). Remarkably, B cell depletion with anti-CD20 antibody attenuated the cardioprotective effects of  
pirfenidone (Figure 6), suggesting that although the effects of  pirfenidone were B cell dependent, they were 
not necessarily mediated by decreasing the number of  B cells in the injured heart. Third, treatment with 
pirfenidone altered the biological response to tissue injury of  myocardial CD19+CD11b+ lymphocytes and 
of  a population of  CD19+CD11b–CD23–CD21–IgMloIgDhi lymphocytes in vivo (Supplemental Figure 6), 
as well as decreased the expression CD86 on B cells in vitro and in vivo (Figure 7). While our data do not 
exclude an effect of  pirfenidone on other cell types, viewed together the above observations suggest that pir-
fenidone is cardioprotective through a unique mechanism that involves immune modulation of  myocardial 
B cell subsets. Although we did not observe an antifibrotic effect of  pirfenidone after I/R injury, as has been 
reported previously by some (4, 5, 7, 9–12), but not all groups (8), this discrepancy may be secondary to 
differences in the experimental models used and the duration and/or doses of  pirfenidone that were used.
Myocardial B lymphocytes in health and disease. Recent studies have shown that several discrete popula-
tions of  leukocytes reside in the normal adult murine myocardium. Antigen-presenting mononuclear cells 
(CD11b+CD11c+F4/80+ and MHCII+) represent the most prominent population, followed by B cells, mono-
cytes, and T cells (20). Although there has been tremendous recent interest in the role of  macrophages, den-
dritic cells, and T cells in the heart, comparatively less is known about the role of  B cells. Very little is known 
about the composition of  myocardial B cells in naive hearts. Ramos et al. have shown that the naive adult 
murine myocardium harbors 2 populations of  B220+ (CD45R) lymphocytes, a larger population of  IgMhiIg-
Dlo cells, and a smaller population of  IgMloIgDhi cells (21); however, neither the ontology nor functional role 
of  these 2 populations of  lymphocytes was characterized in this study. The existing literature suggests that B 
lymphocytes play an important role in chronic LV remodeling following cardiac injury, although the specific 
B cell–mediated mechanisms have not been identified completely. Three different groups have studied the 
role of  myocardial B lymphocytes following acute coronary ligation (MI). Both Yan et al. (22) and Zouggari 
et al. (23) reported that the number of  myocardial CD19+ cells increased after MI. Zouggari showed that 
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Figure 7. Analysis of B cell activation in wild-type and TIRAP-deficient immune cells. (A and B) Unfractionated peri-
toneum-derived inflammatory cells (PDICs) were collected on day 4 after intraperitoneal injection of thioglycollate and 
placed in culture. Cells were cultured in media alone (control), in the presence of necrotic cell extracts from H9c2 cells 
(NCEs), in the presence of NCEs and pirfenidone (NCE-PFD), in the presence of LPS (LPS), or in the presence of LPS and 
pirfenidone (LPS-PFD). After 24 hours of culture, cells were collected for flow cytometric analysis and the prevalence of 
CD19+CD86hi cells was quantified. Three biological replicates per experiment are reported. (A) Results from inflamma-
tory cells collected from wild-type mice. (B) Results from inflammatory cells collected from TIRAP–/– animals. (C and D) 
B lymphocytes were purified from the spleen and cultured for 24 hours under the same conditions described for panels 
A and B. After 24 hours of culture, cells were collected for flow cytometric analysis and the prevalence of CD19+CD86hi 
cells was quantified. Three biological replicates per experiment are reported. Panel C shows results from splenic B cells 
purified from wild-type mice, and panel D shows results from B lymphocytes collected from TIRAP–/– animals. (E and 
F) Mice were subjected to acute myocardial injury either by exposure to diphtheria toxin (DT) (E) or through 90 minutes 
of closed-chest ischemia followed by reperfusion (I/R) (F). Mice were fed regular chow (control) or chow enriched with 
pirfenidone (PFD). On day 4 after injury, the myocardium was collected and analyzed via flow cytometry to assess the 
number of myocardial CD19+CD86hi cells. In E, n = 4 per/group; in F, n = 4 control, n = 5 PFD. *P < 0.05, ***P < 0.001. 
Bars represent the mean, and error bars represent standard deviation. P values were calculated with 1-way ANOVA 
followed by Tukey’s test for multiple comparisons in panels A–D and with Student’s t test in panels E and F.
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CD19+IgD+IgMlo B lymphocytes influx into the infarcted myocardium and contribute to adverse LV remod-
eling by recruiting Ly6C+ monocytes from the bone marrow through a CCL7-dependent mechanism (23). In 
contrast, a recent study found that CD19+ cells are recruited preferentially to fat-associated lymphoid clusters 
in pericardial adipose tissue, with minimal detection of  CD19+ cells in the myocardium after MI (24). Using 
a nonsurgical model of  cardiac injury, Cordero-Reyes et al. showed that adverse cardiac remodeling was 
attenuated by antibody-dependent depletion of  B cells in WT mice (25). Although the mechanisms of  action 
of  B lymphocyte–mediated myocardial damage have not been fully elucidated, there are several mechanisms 
that have been proposed, including dysregulation of  B cell subpopulations (B1 vs. B2 vs. regulatory B cells), 
deposition of  IgM or IgG antibodies, as well as B cell–mediated recruitment of  Ly6C+ monocytes (23). In this 
regard, it is interesting to note that Zhang et al. showed that natural IgMs play a role in myocardial I/R injury, 
although they did not specifically study myocardial B lymphocytes (26).
The results of  the present study both confirm and expand on prior studies that have described myo-
cardial B lymphocytes and suggested that B lymphocytes play an important role in modulating adverse 
cardiac remodeling following cardiac injury. Here we show for the first time to our knowledge that in naive 
murine hearts the majority of  B lymphocytes are CD19+CD11b–CD21–CD23–CD11c–IgD+IgMlo/–, whereas 
a minority of  myocardial B lymphocytes are CD19+CD11b+. In this latter group, a smaller fraction express 
CD5, which is characteristic of  B1a lymphocytes, and a larger fraction is CD5–, which is characteristic of  
B1b lymphocytes (16). Although the phenotype of  the CD19+CD11b– cells that we describe overlaps the 
phenotypic description of  the B cells that accumulated in the myocardium after infarction in the report by 
Zouggari et al. (i.e., CD19+IgD+IgMlo), it bears emphasis that the precise ontogeny of  the CD19+CD11b–
CD21–CD23–CD11c–IgD+IgMlo/– cells described herein is not known. To our knowledge, the phenotype 
of  these cells does not match the profile of  any previously described B cell subset (27). B cells can be 
broadly characterized into B1 and B2 lymphocytes, which are classically considered innate and adaptive, 
respectively. Whereas B1a lymphocyte development occurs primarily during fetal and perinatal life, B1b 
and B2 lymphocyte production continues throughout adult life. The observation that these cells express 
relatively high levels of  IgD, which is characteristic of  B2 cells, and low levels of  IgM, which are character-
istically expressed by B1 cells, suggests that these cells are not B1 cells (23). Of  note, several authors have 
reported that a distinct population of  mature CD19+CD21–CD23– B cells accumulate in aging mice (28). 
However, these age-associated B cells are CD11c+ and express the transcription factor T-bet, whereas we 
did not detect CD11c expression via FACS, nor gene expression of  T-bet by RNA sequencing (data not 
shown). Our results further expand on the existing literature on myocardial B cells also by showing that 
unique subsets of  B lymphocytes increase in the heart following I/R injury (Figure 5), and that different 
subsets of  myocardial B lymphocytes (CD19+CD11b+ and CD19+CD11b– lymphocytes) are activated dif-
ferentially following cardiac injury, in a process that is modulated by pirfenidone (Supplemental Figure 6). 
Although we did not observe a statistically significant increase in CD19+ lymphocytes in the heart after 
DT-mediated cardiac injury, the overall trends were similar to those observed with I/R injury. The quan-
titative differences in B cell response may be secondary to differences in the degree of  tissue injury and/or 
differences in B lymphocyte kinetics in the 2 different injury models.
Our findings suggest that B cells are required for the cardioprotective effects of  pirfenidone after acute tis-
sue injury and that B cell depletion does not mimic the cardioprotective effects of  pirfenidone following tissue 
injury in vivo. Although these results are seemingly incongruent at first blush, they suggest a more nuanced 
model supported by our transcriptional profiling studies in vivo (Supplemental Figure 6), wherein pirfenidone 
exerts its beneficial effects by modulating the immune response of  B cells to tissue injury. Based on the results 
of  our informatics analysis we hypothesized that activation of  TLR signaling in response to the release of  the 
cytosolic contents from necrotic cells (i.e., DAMPS) might activate B cells through a pirfenidone-sensitive 
process. We found that NCEs were sufficient to upregulate the costimulatory molecule CD86 in B lympho-
cytes isolated from cultures of  mixed inflammatory cells, whereas NCEs were not sufficient to upregulate 
CD86 in purified B cell preparations. In contrast, LPS, a classic TLR4 agonist, induced upregulation of  CD86 
in CD19+ cells in PDICs as well as in purified B cell preparations. These findings are consistent with prior 
reports showing that the B lymphocyte response to TLR agonists is context dependent (29), and suggest that B 
lymphocyte activation in response to NCE is, at least in part, non–cell autonomous. Importantly, we observed 
that pirfenidone significantly attenuated the number CD19+CD86+ lymphocytes in PDIC cultures stimulated 
with NCEs or LPS. Consistent with our in vitro studies, we observed that there was a significant decrease in 
CD19+CD86hi lymphocytes in the hearts of  DT-injured and I/R-injured mice treated with pirfenidone when 
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compared with untreated controls (Figure 7, E and F). Our in vitro results with TIRAP–/– cells (Figure 7) sug-
gest that activation of  B cells by NCEs is TIRAP dependent. However, LPS-induced activation of  B cells in 
vitro was attenuated but not abrogated in TIRAP–/– mice. This is consistent with prior observations that LPS 
signaling can activate multiple intracellular pathways in B cells (30).
Our work has some important limitations. First, we did not specifically compare the effect of  pir-
fenidone and anti-CD20 treatment. Second, we did not measure the effect of  pirfenidone treatment in 
IgG-treated animals. In addition, we did not determine which actions of  B cells accentuate adverse remod-
eling following acute myocardial injury. Further work will be needed to detail the cell-autonomous versus 
non–cell-autonomous role of  TIRAP during B cell activation in the context of  the acute inflammatory 
response to sterile injury, to understand if  pirfenidone-mediated modulation of  B cells is dependent on the 
modulation of  other signaling pathways, including TGF-β signaling, and to define the mechanistic basis of  
B cell contribution to adverse cardiac remodeling.
Although the scope of  these studies was not intended to define the molecular mechanisms of  pirfeni-
done, our findings are consistent with prior reports that have shown that pirfenidone inhibits TLR signaling 
through the MAPK signaling cascade (31), as well as studies that show that pirfenidone inhibits MAPK sig-
naling in the heart (10, 12). Importantly, this is the first study to our knowledge that demonstrates a direct 
cellular target that mediates the beneficial effects of  pirfenidone in vivo.
In our work we found that pirfenidone-dependent immunomodulation of  the cardiac inflammatory 
infiltrate improved cardiac function after acute injury. Surprisingly, treatment with pirfenidone was not 
associated with a reduction in troponin on day 4 after administration of  DT (Figure 1B) nor a reduction 
in infarct size after I/R injury, as assessed by trichrome staining (Figure 3, G and H). This finding suggests 
that cardiac B lymphocytes might modulate cardiac remodeling after injury. Further work will be needed to 
understand the significance of  this intriguing observation.
Conclusions. Although it has been long recognized that the innate immune system plays an important 
role in the adverse cardiac remodeling and myocardial dysfunction that ensues following acute myocar-
dial injury, the quest to identify viable therapeutic targets has been illusory to date, because of  the inher-
ent duality of  the innate immune response, which is required for initiating cardiac repair following tissue 
injury (32). Here we show a previously unappreciated complexity of  the B lymphocyte component of  the 
acute inflammatory response triggered by acute myocardial damage, and we show that B cells’ response 
to myocardial injury can be modulated through a small-molecule-based approach, as opposed to an anti-
body-based approach. This raises the interesting question of  whether pirfenidone might be repurposed as 
an immunomodulatory agent in the setting of  I/R injury following percutaneous cardiac angioplasty for 
ST-segment myocardial infarction. In contrast to monocytes/macrophages, which are essential for cardiac 
repair, B lymphocytes function, at least in part, by modulating interactions between T cells, cardiac macro-
phages, and dendritic cells. Accordingly, immunomodulatory strategies that are designed to target B cells 
may be less likely to lead to untoward effects, than are strategies that are aimed at cytokines and cell types 
that are critical for myocardial repair. Lastly, given the increasing recognition of  the importance of  B lym-
phocytes in the heart (23–25), these studies may also serve the heuristic purpose of  focusing future studies 
on better understanding the origins, dynamics, temporal development, and functional significance of  the 
myocardial B lymphocytes in health, disease, and aging.
Methods
Mouse injury models
To evaluate the effects of  pirfenidone on acute myocardial injury, we used 2 distinct in vivo experimen-
tal models of  myocardial injury: a nonsurgical model of  selective cardiac myocyte cell death (13) and a 
well-characterized surgical model of  closed-chest I/R injury (15, 33). The mice for these experiments were 
bred and maintained at the Washington University School of  Medicine and all experimental procedures 
were done in accordance with the animal use oversight committee.
DT-induced injury model. Mlc2v-Cre mice (C57BL/6J, Jackson Laboratories) were crossed to Rosa26-DT 
mice (C57BL/6J) to generate lines of Rosa26-DTMlc2v-Cre mice. Female mice, 9–40 weeks of age, were injected 
i.p. with 2.5 ng/g of DT (Sigma-Aldrich). DT was solubilized according to the manufacturer’s instructions and 
stored in aliquots at a concentration of 2,000 ng/μl at –80°C. Aliquots stored at –80°C were diluted to 20 ng/
μl in PBS 1–10 days prior to use and stored at –20°C. DT was diluted to a final concentration of 1 ng/μl in PBS 
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immediately prior to injections. Littermate controls were used for each experiment. Mice were treated and stud-
ied as they became available and the results from all available experiments were compiled for analyses.
To assess the extent of  myocyte injury following DT-induced injury, we measured troponin release and 
Evan’s blue dye uptake. Troponin was measured day 4 after injection of  DT at the time of  terminal sacri-
fice. Blood was collected in BD Microtainer tubes and the serum was diluted 1:4 in PBS (50 μl serum + 150 
μl PBS). Serum troponin was measured using a commercial chemiluminescent microparticle assay (Abbot 
Laboratories). Evan’s blue dye uptake was assessed on day 4 after DT injection, as described previously 
(34, 35). Hearts were examined at the level of  the papillary muscle using ImageJ software (NIH). Data are 
expressed as the percentage area of  the myocardium with red fluorescence.
I/R injury. Hearts from WT mice (C57BL/6J) were subjected to I/R injury using the closed-chest I/R 
model developed by Entman and colleagues (33), and modified as we have described previously (15). For 
the studies described herein we used 9- to 10-week-old mice that were instrumented, then at 1 week after 
instrumentation were anesthetized with 1.5% isoflurane, and subjected to 90 minutes of  closed-chest isch-
emia, followed by reperfusion for 2 weeks.
Pirfenidone treatment
In order to administer pirfenidone, mice were fed powdered chow mixed with pirfenidone (eNovation Chem-
icals, catalog D404655) at 0.5% by weight or powdered chow alone. This dosage has been commonly used in 
rodent models and has been suggested to result in plasma concentrations similar to those observed in humans 
treated with pirfenidone (36). Unless specifically noted, mice were switched to a diet enriched with pirfeni-
done 3 days prior to DT-induced injury or I/R injury, and maintained on this diet throughout the duration 
of  the experiments. In parallel studies, we fed mice normal chow prior to I/R injury and then administered 
pirfenidone acutely at the time of  cardiac injury. For these latter studies, mice were injected i.p. with diluent 
(200 μl PBS) or i.p. with pirfenidone (200 μl of  pirfenidone, 5 mg/ml in PBS) after reperfusion and the morn-
ing after I/R injury (2 injections total). They were switched to pirfenidone-enriched diet or control diet the 
evening of  I/R injury and maintained on the same diet until completion of  the experiment.
B cell depletion
For the B cell depletion studies, mice were injected with 100 μg of  anti-CD20 antibody (Biolegend, clone 
SA271G2, catalog 152104) through the jugular vein. The injected antibody was diluted in PBS, pH 7.2, 
containing no preservative (endotoxin level < 0.01 U/μg of  protein) and filtered using a 0.2-μm filter. 
Immunodepletion was assessed at different time points, as described in the results section.
Gravimetric and histological analysis
Rosa26-DTMlc2v-Cre and littermate control WT mice were euthanized 14 days after DT injection, and the hearts 
were removed and weighed to determine the heart weight/tibia length ratio. WT mice were euthanized 14 
days after I/R injury and the hearts were removed and weighed to determine the heart weight/tibia length 
ratio. Hearts were processed, paraffin-embedded, and stained with hematoxylin and eosin and Masson’s tri-
chrome, as described previously (37). TUNEL staining was performed with the Millipore S7200 ApopTag 
Peroxidase In Situ Oligo Ligation Apoptosis Detection Kit according to the manufacturer’s instructions.
Echocardiographic studies
Image acquisition. Ultrasound examination of the cardiovascular system was performed using a Vevo 2100 Ultra-
sound System (VisualSonics Inc.) equipped with a 30-MHz linear-array transducer, as previously described (15).
Imaging protocol. Mice were imaged by echocardiography at the time of  ischemia and 2 weeks after 
reperfusion to evaluate LV structure and function, as described previously (38). The echocardiographer was 
blinded to study group assignment. Animals with poor acoustic windows or small areas at risk (<0.45) at 
the time of  ischemia were excluded from further analysis.
Cell culture
PDICs were harvested from the peritoneal cavity of  thioglycolate-stimulated WT and TIRAP–/– mice. PDIC 
cultures contain an admixture of  inflammatory cells, including CD19+ B cells (39). TIRAP-deficient mice 
were a gift from Ruslan Medzhitov (Yale University, New Haven, Connecticut, USA). PDICs were harvest-
ed on day 4 after i.p. injection of  1 ml of  thioglycolate medium (Millipore). Mice were euthanized, and the 
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peritoneal cavity was washed 3–4 times with 3 ml of  DMEM containing 10% FCS. A 3-ml syringe with an 
18-gauge needle was used to inject the peritoneal cavity and retrieve the medium containing PDICs. Har-
vested cells were centrifuged at 250 g for 5 minutes, resuspended in 5 ml of  media, and then filtered through 
a 40-μm strainer. Cells were plated at approximately 1.5 million cells/ml in 12- or 24-well plates. Primary 
spleen-derived B lymphocytes were isolated with the MagniSort Mouse B cell Enrichment Kit (Invitrogen) 
according to manufacturer’s instructions and plated in 96-well plates at 1 million cells/ml. The purity of  
isolated B cells was checked by flow cytometry and was greater than 85% in all reported experiments. Both 
PDICs and primary B lymphocytes were cultured in DMEM with 10% FCS, 1 mM sodium pyruvate, 
penicillin/ streptomycin (GIBCO, 1×), 2 mM L-glutamine, 10 mM Hepes, and 55 μM 2-mercaptoethanol.
We used LPS-EB ultrapure LPS (InvivoGen) or NCEs to stimulate the cell cultures. For stimulation 
with LPS, LPS was added at 100 ng/ml at the time of  plating. NCEs were prepared from H9c2 cells, in a 
similar manner to the protocol described for mouse heart and mouse liver extracts (18). For stimulation, 
NCEs were added at a final concentration of  10 μg/ml at the time the cells were plated. LPS and NCE 
stimulation was performed in the presence and absence of  pirfenidone for 24 hours. Pirfenidone was solu-
bilized (10 mg/ml) in DMEM by 2 rounds of  gentle heating in a water bath at 65°C for 5 minutes, followed 
by vortexing for 20 seconds. The pirfenidone solution was stored at 4°C and used within 24 hours of  prepa-
ration. Pirfenidone was added at a final concentration of  150 ng/ml. For FACS analysis, both adherent 
and nonadherent cultured cells were collected. Nonadherent cells were collected by pipetting up and down 
in the culture media prior to media collection and a single rapid wash with Cell Stripper (Corning), and 
then gently centrifuged at 250 g for 3 minutes. To collect the adherent fraction, cells were incubated for 30 
minutes at 37°C with Cell Stripper and then detached by gentle pipetting followed by mechanical detach-
ment with a cell lifter. The adherent cells were mixed with the nonadherent cells, spun down at 250 g for 3 
minutes, and resuspended in 300 μl of  FACS buffer for further processing.
Flow cytometry
For flow cytometry experiments, mice were euthanized in a CO2 chamber and the hearts were perfused 
with cold PBS, carefully dissected from extracardiac tissue under a stereo microscope, finely minced, sus-
pended in 3 ml of  DMEM, and then digested with 120 U of  DNAse (Sigma-Aldrich), 180 U of  hyaluro-
nidase (Sigma-Aldrich), and 1,350 U of  collagenase (Sigma-Aldrich) for 60 minutes at 37°C. The digested 
material was filtered through 40-μm filters and pelleted by centrifugation (250 g for 3 minutes at 4°C) in 
HBSS supplemented with 2% FCS plus 0.2% bovine serum albumin (BSA). Red blood cells were lysed in 
ACK lysis buffer (Invitrogen) for 15 minutes on ice and the remaining cells were resuspended in 300 μl of  
FACS buffer (PBS with 2% FCS and 2 mM EDTA). Cultured cells were collected for FACS analysis as 
described above and resuspended in 300 μl of  FACS buffer. Samples were labeled with fluorescently con-
jugated antibodies. A list of  all antibodies used including brand, clone number, and fluorophores used are 
provided in Supplemental Table 3. Cells were stained for 45 minutes on ice, and washed in FACS buffer pri-
or to analysis. All antibodies from BioLegend were used at 0.2 μl per 300 μl sample, while antibodies from 
BD Biosciences were used at 0.4 μl per 300 μl sample. FACS was performed on Becton Dickinson analyzers 
(LSRII, Canto, X20, or Fortessa). Compensation controls were generated using UltraComp eBeads (Invit-
rogen) and verified on single-color control samples obtained by staining primary splenocytes. Gating strat-
egies are summarized in Supplemental Figures 1, 3, and 4. For flow cytometry experiments that involved 
the DT injury model, we collected serum via retro-orbital puncture immediately prior to terminal sacrifice 
for quantification of  troponin. In pilot studies we observed that mice with a serum troponin below 1 ng/ml 
did not have appreciable tissue injury; therefore, mice with serum troponin below 1 ng/ml were excluded 
from further analysis. Cell sorting was performed using a FACSAria instrument (Becton Dickinson) at the 
Washington University Department of  Pathology Flow Cytometry and Sorting Core.
Transcriptional profiling
We performed transcriptional profiling of  cardiac lymphocytes that were isolated from naive and DTR-in-
jured hearts in the presence and absence of  pirfenidone. We FACS sorted CD19+CD11b+ and CD19+CD11b– 
cardiac lymphocytes from naive, DT-injured, and DT + pirfenidone hearts directly into lysis buffer for 
RNA isolation. A total of  600 to 12,000 cells were sorted from each heart. RNA was extracted using the 
QuickRNA MicroPrep (Zymo Research), according to the manufacturer’s instructions. RNA was eluted in 
11 μl and the entire volume was submitted for whole-transcriptome analysis. Myocardial B lymphocytes 
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were sorted from 8 naive animals, 6 DT mice, and 3 DT + pirfenidone-treated mice. Total RNA obtained 
from sorted B cell populations was selected for polyadenylated RNA and converted to RNA-sequencing 
libraries using the SMARTer v2 kit from Clontech. Single-end, 50-bp reads were obtained on an Illumina 
HiSeq 3000 and aligned to the Illumina iGenomes GRCm38_Ensembl release of  the mouse transcriptome 
using Tophat2.1 (40), yielding an average of  1.8 × 107 aligned reads per sample. Gene-level quantification 
was performed using HTSeq 2 (41). mRNAs were included in downstream analyses if  present in all biolog-
ical replicates in any of  the 6 experimental groups (CD19+CD11b+ and CD19+CD11b– from WT, DT, and 
DT + pirfenidone) at an abundance of  at least 1 read per million. A total of  12,097 mRNAs were obtained 
from this filtering procedure. In order to compare gene expression respectively in CD19+CD11b+ cells and 
CD19+CD11b– cells across untreated, DT-injured, and DT-injured + pirfenidone conditions, gene expres-
sion data were corrected for variability among experimental batches and a principal components analysis 
across all 12,097 mRNAs for the 17 sequenced samples was performed. This highlighted 5 samples (1 
CD19+CD11b+ DT heart, 2 CD19+CD11b– naive hearts, and 1 CD19+CD11b– DT heart) that were strong 
outliers being outside the 95% confidence interval (2 standard deviations) for their group and that were 
removed from further analysis. The data are available in the NCBI’s Gene Expression Omnibus repository 
(GEO GSE112984). The limma-voom procedure was used to identify mRNAs with differential expression 
between experimental conditions (42). KEGG pathway analysis was performed on mRNAs with greater 
than 2-fold change in expression level between specific experimental groups using the appropriate function-
al annotation module within the 2017 release of  the NIH online resource DAVID (43) and accepting an 
FDR ≤ 0.05 (Benjamini-Hochberg method) to identify pathways enriched between the assigned conditions. 
KEGG pathways within the following 3 categories were analyzed: signal transduction (3.2), signaling mol-
ecules and interactions (3.3), and immune system (5.1).
Statistics
Data are expressed as mean ± standard deviation. Two-tailed Student’s t test was used for pairwise com-
parisons between 2 groups, 1-way ANOVA with Tukey’s correction for multiple post hoc comparisons was 
used to compare multiple experimental groups, while 2-way ANOVA with Tukey’s correction for multiple 
post hoc comparisons was used to compare across multiple experimental groups with multiple conditions 
in each group. The Gehan-Breslow-Wilcoxon method was used to compare Kaplan-Meier curves. A P val-
ue less than 0.05 was considered statistically significant. The specific statistical test used in each experiment 
is indicated in the figure captions. All calculations were made using GraphPad Prism version 7.04.
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